Alkermes plc Share Price Today: Live Updates & Key Insights

Alkermes plc share price today is $52.24, up -0.15%. The stock opened at $53.07 against the previous close of $52.97, with an intraday high of $53.86 and low of $52.48.

Alkermes plc Share Price Chart

Alkermes plc

us-stock
To Invest in {{usstockname}}
us-stock

Alkermes plc Share Price Performance

$52.24 -0.0015(-0.15%) ALKS at 27 Jul 2026 01:55 PM Drug Manufacturers - Specialty & Generic
Lowest Today 52.48
Highest Today 53.86
Today’s Open 53.07
Prev. Close 52.97
52 Week High 55.67
52 Week Low 25.17
Day’s Range: Low 52.48 High 53.86
52-Week Range: Low 25.17 High 55.67
1 day return -
1 Week return +2.12
1 month return -4.17
3 month return +56.7
6 month return +59.42
1 year return +101.98
3 year return +75.84
5 year return +116.86
10 year return -

Alkermes plc Institutional Holdings

BlackRock Inc 16.99

Vanguard Group Inc 10.80

iShares Core S&P Small-Cap ETF 6.03

Baker Bros Advisors LP 6.01

Vanguard Portfolio Management, LLC 5.71

State Street Corp 5.68

Vanguard Capital Management, LLC 4.46

Renaissance Technologies Corp 3.70

American Century Companies Inc 3.64

Vanguard Total Stock Mkt Idx Inv 3.18

T. Rowe Price Associates, Inc. 2.80

Dimensional Fund Advisors, Inc. 2.71

iShares Russell 2000 ETF 2.60

COMMODORE CAPITAL LP 2.52

Geode Capital Management, LLC 2.51

JPMorgan Chase & Co 2.46

Vanguard Small Cap Index 2.29

Deep Track Capital, LP 2.15

Wellington Management Company LLP 1.78

First Trust Advisors L.P. 1.78

PRIMECAP Management Company 1.52

Nuveen, LLC 1.48

Avantis US Small Cap Value ETF 1.45

Holocene Advisors, LP 1.39

First Trust NYSE Arca Biotech ETF 1.37

State Street® SPDR® S&P® Biotech ETF 1.36

Citadel Advisors Llc 1.34

Vanguard Small Cap Growth Index Inv 1.32

Vanguard Institutional Extnd Mkt Idx Tr 1.15

T. Rowe Price US Mid-Cap Value Equity 1.07

JPM US Mid Cap Growth-Composite 1.07

Vanguard Capital Opportunity Inv 1.03

Fidelity Small Cap Index 0.96

State Street SPDR Port S&P 600 Sm CpETF 0.92

iShares S&P Small-Cap 600 Growth ETF 0.90

T. Rowe Price Mid-Cap Value 0.87

iShares Russell 2000 Growth ETF 0.74

iShares Biotechnology ETF 0.70

Vanguard Tax-Managed Small Cap Adm 0.65

Russell 2000 Equity Index Fund B 0.61

Alkermes plc Market Status

Strong Buy: 8

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

Alkermes plc Fundamentals

Market Cap 8828.82 M

PB Ratio 4.9997

PE Ratio 58.8556

Enterprise Value 9826.94 M

Total Assets 2530.26 M

Volume 1288506

Alkermes plc Company Financials

Annual Revenue FY25:1475899000 1475.9M, FY24:1557632000 1557.6M, FY23:1590604000 1590.6M, FY22:1111795000 1111.8M, FY21:1173751000 1173.8M

Annual Profit FY25:1273842000 1273.8M, FY24:1312301000 1312.3M, FY23:1353696000 1353.7M, FY22:893687000 893.7M, FY21:569838000 569.8M

Annual Net worth FY25:241664000 241.7M, FY24:367070000 367.1M, FY23:214724000 214.7M, FY22:-158267000 -158.3M, FY21:-48169000 -48.2M

Quarterly Revenue Q1/2026:392911000 392.9M, Q4/2025:384547000 384.5M, Q3/2025:394185000 394.2M, Q2/2025:390657000 390.7M, Q1/2025:306510000 306.5M

Quarterly Profit Q1/2026:331333000 331.3M, Q4/2025:332738000 332.7M, Q3/2025:342594000 342.6M, Q2/2025:341197000 341.2M, Q1/2025:257313000 257.3M

Quarterly Net worth Q1/2026:-66480000 -66.5M, Q4/2025:49341000 49.3M, Q3/2025:82761000 82.8M, Q2/2025:87098000 87.1M, Q1/2025:22464000 22.5M

About Alkermes plc & investment objective

Company Information Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Organisation Drug Manufacturers - Specialty & Generic

Employees 2050

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Richard F. Pops

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Alkermes plc FAQs

What is the share price of Alkermes plc today?

The current share price of Alkermes plc is $52.24.

Can I buy Alkermes plc shares in India?

Yes, Indian investors can buy Alkermes plc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Alkermes plc shares in India?

You can easily invest in Alkermes plc shares from India by:

Can I buy fractional shares of Alkermes plc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Alkermes plc?

Alkermes plc has a market cap of $8828.82 M.

In which sector does Alkermes plc belong?

Alkermes plc operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Alkermes plc stocks?

To invest, you typically need:

What is the PE and PB ratio of Alkermes plc?

The PE ratio of Alkermes plc is 58.86 and the PB ratio is 5.00.